In patients with pancreatic cancer, responders to gastrin-17-diphtheria toxoid immunogen (G17DT), which is an anti-gastrin antibody, showed a significantly longer survival than antibody non-responders [55,56]. Here, GAST is linked to familial pancreatic carcinoma.